Clinical Trials Logo

Endometrial Cancer clinical trials

View clinical trials related to Endometrial Cancer.

Filter by:

NCT ID: NCT00003624 Terminated - Ovarian Cancer Clinical Trials

Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer

Start date: December 1998
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of amifostine in reducing the risk of side effects caused by cisplatin and paclitaxel in treating women who have ovarian, peritoneal, cervical, fallopian tube, uterine, or endometrial cancer.

NCT ID: NCT00003179 Terminated - Endometrial Cancer Clinical Trials

Surgery Plus Medroxyprogesterone in Preventing Endometrial Cancer

Start date: November 1998
Phase: Phase 2
Study type: Interventional

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of surgery with or without medroxyprogesterone may be an effective way to prevent the development of endometrial cancer in patients who have endometrial hyperplasia. PURPOSE: Phase II trial to compare the effectiveness of surgery alone with that of medroxyprogesterone followed by surgery in preventing endometrial cancer in patients who have endometrial hyperplasia.

NCT ID: NCT00002976 Terminated - Endometrial Cancer Clinical Trials

Estrogen Replacement Therapy in Treating Women With Early-Stage Endometrial Cancer

Start date: June 1997
Phase: Phase 3
Study type: Interventional

RATIONALE: Estrogen replacement therapy may improve quality-of-life in postmenopausal women with endometrial cancer. It is not yet known whether estrogen replacement therapy will affect cancer recurrence. PURPOSE: Randomized double-blinded phase III trial to determine the effectiveness of estrogen replacement therapy in treating women who have stage I or stage II endometrial cancer.